Articles tagged with “alk-inhibitor”

GSK Nuvalent Acquisition: ROS1/ALK NSCLC TKI Pipeline

Analyze GSK’s $10.6B Nuvalent acquisition. Learn about zidesamtinib & neladalkib, their clinical trial data, and the ROS1/ALK NSCLC competitive landscape.

40 min read

6/14/2026

gsk nuvalent zidesamtinib neladalkib nsclc ros1 inhibitor alk inhibitor precision oncology tyrosine kinase inhibitors